Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

Healthcare Medical Devices
CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool, which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA) and computed tomography angiography (CTA). The CSS is non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers.


TSXV:CVM.H - Post by User

CVR Medical Corp > Financials on Sedar
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by Looneytuneson Aug 12, 2020 6:02am
183 Views
Post# 31396396

RE:Financials on Sedar

RE:Financials on SedarThe overall timeline to FDA approval and subsequent sales is still undetermined as working capital is necessary to complete the new clinical trials and developmental work, however the company is targeting Q1 2022 for planning and budgetary purposes.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities